The prognostic role of MAC30 in advanced gastric cancer patients receiving platinum-based chemotherapy.

Aim: We aimed to investigate a practical profile of MAC30 on chemotherapeutic response in gastric cancer (GC).

Patients & Methods: We elected 87 GC patients receiving platinum-based chemotherapy in this study. MAC30 levels in tumor and adjuvant nontumor tissues were confirmed via reverse transcription-PCR to identify the clinical profile in GC and the correlation with therapeutic response.

Results: We found elevated MAC30 in GC compared with the matched adjacent nontumor tissues. GC with enhanced MAC30 exhibited poorer survival by Kaplan-Meier analysis and poor response to adjuvant platinum-based chemotherapy. A multivariate analysis showed that MAC30 was an independent prognostic factor of overall survival in GC receiving platinum-based chemotherapy.

Conclusion: MAC30 could play as a potential biomarker for prognosis of GC with platinum-based chemotherapy.